Table 4. Serum Hormone Concentrations at Baseline and After 3 and 6 Months of LMMS or Placebo in Young Women With Anorexia Nervosa.
| Measure | Baseline median (IQR) | Adjusted median (IQR)a | Median (IQR) of change from 0 to 6 mo | P value (within group) | 95% CI for median difference (0-6 mo within group) | P value (difference in change between groups) | 95% CI for difference in median change between groups | |
|---|---|---|---|---|---|---|---|---|
| 3 mo | 6 mo | |||||||
| IGF-1 | ||||||||
| LMMS | 154.0 (105.6 to 215.5) | 163.3 (133.6 to 199.3) | 171.9 (133.8 to 196.6) | 4.5 (−15.9 to 11.6) | .67 | −15.45 to 11.24 | .39 | −30.40 to 20.40 |
| Placebo | 161.9 (129.5 to 225.0) | 167.3 (146.9 to 212.9) | 172.3 (144.0 to 206.0) | 2.8 (−27.6 to 3.5) | .76 | −23.29 to 19.63 | ||
| Insulin | ||||||||
| LMMS | 8.8 (5.3 to 32.9) | 19.5 (13.6 to 23.7) | 14.7 (12.1 to 17.5) | 3.4 (−17.3 to 5.61) | .40 | −9.10 to 5.16 | .20 | −14.96 to 17.83 |
| Placebo | 11.8 (5.13 to 28.2) | 17.8 (14.1 to 21.6) | 15.4 (14.3 to 16.8) | 5.1 (−14.0 to 11.6) | .48 | −12.63 to 10.05 | ||
| Cortisol | ||||||||
| LMMS | 10.1 (8.4 to 14.4) | 9.9 (7.8 to 13.3) | 12.0 (9.5 to 14.0) | 2.8 (−3.5 to 4.7) | .32 | −1.66 to 4.62 | .84 | −5.03 to 4.29 |
| Placebo | 10.7 (7.6 to 14.0) | 9.8 (8.3 to 11.1) | 12.2 (7.6 to 14.0) | 2.1 (−1.4 to 5.5) | .26 | −0.69 to 5.32 | ||
| Adiponectin | ||||||||
| LMMS | 20.9 (18.6 to 27.8) | 21.2 (19.7 to 24.4) | 20.0 (19.0 to 21.0) | −2.7 (−6.5 to 0.4) | .12 | −6.15 to 0.31 | .95 | −6.09 to 4.88 |
| Placebo | 21.5 (18.1 to 27.8) | 20.9 (19.7 to 22.2) | 20.2 (19.4 to 20.9) | −1.7 (−8.3 to 1.6) | .11 | −8.08 to 0.35 | ||
| Leptin | ||||||||
| LMMS | 2.3 (2.0 to 3.8) | 2.6 (2.4 to 2.7) | 3.2 (1.3 to 4.3) | 0.8 (−2.6 to 2.6) | .89 | −2.63 to 2.57 | .78 | −2.60 to 3.28 |
| Placebo | 2.7 (2.2 to 3.0) | 2.5 (2.4 to 2.7) | 2.2 (1.2 to 3.9) | −0.2 (−2.0 to 0.6) | .65 | −1.79 to 0.46 | ||
Abbreviations: IGF-1, insulin-like growth factor 1; LMMS, low-magnitude mechanical signals.
a
Adjusted for patient age, duration of anorexia, weight gain from 0 to 6 months, and adherence (median platform-recorded minutes used per 3-month period). Patient age and duration of anorexia were consistently significant in most models. Adherence was significant only in some models.